GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (NSE:LUPIN) » Definitions » Total Liabilities

Lupin (NSE:LUPIN) Total Liabilities : ₹96,237 Mil (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lupin Total Liabilities?

Lupin's Total Liabilities for the quarter that ended in Mar. 2024 was ₹96,237 Mil.

Lupin's quarterly Total Liabilities declined from Sep. 2023 (₹101,366.50 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹96,237.30 Mil).

Lupin's annual Total Liabilities increased from Mar. 2022 (₹95,992.40 Mil) to Mar. 2023 (₹104,131.10 Mil) but then declined from Mar. 2023 (₹104,131.10 Mil) to Mar. 2024 (₹96,237.30 Mil).


Lupin Total Liabilities Historical Data

The historical data trend for Lupin's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Total Liabilities Chart

Lupin Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124,026.90 97,523.30 95,992.40 104,131.10 96,237.30

Lupin Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104,131.10 - 101,366.50 - 96,237.30

Lupin Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lupin's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=85015+(1552.8+9669.5
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=96,237

Total Liabilities=Total Assets (A: Mar. 2024 )-Total Equity (A: Mar. 2024 )
=239971.8-143734.5
=96,237

Lupin's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=85015+(1552.8+9669.5
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=96,237

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=239971.8-143734.5
=96,237

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lupin Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lupin's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Lupin (NSE:LUPIN) Business Description

Traded in Other Exchanges
Address
Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400 055
Lupin Ltd is a specialty and generic drug manufacturing company. The company's global formulations business develops and delivers a wide range of branded and generic formulations across the globe. The operations of the company are limited to one segment, namely pharmaceuticals and related products. The company also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India.

Lupin (NSE:LUPIN) Headlines

No Headlines